Author/Authors :
Wang Ling نويسنده , Han Lei نويسنده , Xu Jiru نويسنده The First Affiliated Hospital, Xi’an Jiaotong University Health Science Center, Xi’an, China , GUO Yijie نويسنده Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi’an Jiao Tong University, Xi’an, China , Lei Jine نويسنده Clinical Laboratory, The First Affiliated Hospital of
Xi’an Jiao Tong University, Xi’an Jiao Tong University, Xi’an
710061, China
Abstract :
Background Human cationic antibacterial peptide hCAP18/LL-37 is
the only known cathelicidin, which is part of the innate immune system
of humans. The antimicrobial activity of LL-37 against
multi-drug-resistant Acinetobacter baumannii has been
reported recently, however, whether LL-37 and its analogues (LL/CAP18
and FF/CAP18) have antimicrobial activity against pan-drug-resistant
Acinetobacter baumannii (PDRAB) is still unknown.
Objectives This study aims to clarify the antimicrobial activity of
LL-37 and its analogues against PDRAB. Methods In this study, we
evaluated LL-37 and its truncated analogs inhibitory effect on the
growth of PDRAB by minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) analysis, we also examined the effect
of LL-37 and its analogs on bacterial biofilm formation by using a
quantitative crystal violet assay. Results LL-37 and its truncated
analogs were effective in inhibiting the growth of PDRAB and had a rapid
killing ability. After exposure to the peptides, the development of the
PDRAB biofilm was inhibited. Strong inhibitory and dispersion effects of
FF/CAP18 on the biofilm were confirmed by fluorescence microscopy and
field emission scanning electron microscopy. Conclusions This results
show that FF/CAP18 is a potential antimicrobial agent for treating
pan-drug–resistant bacterial infections.
